Source-grounded facts extracted from CervoMed Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CervoMed Inc. entered into Engagement Letter with H.C. Wainwright & Co., LLC (effective 2026-06-16).
“On June 16, 2026, the Company entered into an engagement letter, in connection with the Offering (the “Engagement Letter”), with H.C. Wainwright & Co., LLC (“Wainwright”), pursuant to which Wainwright agreed to serve as the exclusive placement agent for the issuance and sale of securities of the Company pursuant to the Purchase Agreement.”
CervoMed Inc. entered into Securities Purchase Agreement valued at $10.0 million (effective 2026-06-18).
“On June 18, 2026, CervoMed Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein (the “Investors”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors (the “Offering”), 2,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), at a purchase price of $4.00 per Share, for aggregate gross proceeds of $10.0 million, before deducting placement agent fees (as described in greater detail below) and related offering expenses.”
CervoMed Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $10.5 million (effective 2026-06-09).
“On June 9, 2026, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), for the private placement (the “Private Placement”) of an aggregate of 3,360,377 units (the “Units”)”
CervoMed Inc. shareholders approved Amendment No. 1 to the 2025 Equity Incentive Plan at the 2026-06-08 meeting.
“To approve Amendment No. 1 to the CervoMed Inc. 2025 Equity Incentive Plan.”
CervoMed Inc. shareholders approved Advisory approval of executive compensation for fiscal year 2024 at the 2026-06-08 meeting.
“To approve, on an advisory basis, the compensation of the Company’s named executive officers during the year ended December 31, 2024, as disclosed in the Proxy Statement.”
CervoMed Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for 2026 at the 2026-06-08 meeting.
“To ratify the selection of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.”
CervoMed Inc. shareholders approved Election of eight directors at the 2026-06-08 meeting.
“The election of each nominee pursuant to Proposal No. 1 required the affirmative vote of a plurality of the votes present and entitled to vote at the Annual Meeting and, accordingly, each nominee received the requisite number of votes for election at the Annual Meeting.”
CervoMed Inc. reported financial results for the full year ended December 31, 2025.
“CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided corporate updates.”
CervoMed Inc. reported financial results for the fourth quarter ended December 31, 2025.
“CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided corporate updates.”
William Tanner was terminated as Chief Financial Officer at CervoMed Inc..
“Dr. Tanner’s employment with the Company will terminate effective May 31, 2024, and, effective June 1, 2024, Dr. Tanner will begin service as a consultant to the Company.”
William Elder was appointed as Chief Financial Officer at CervoMed Inc..
“appointed William Elder, the Company’s current General Counsel, Corporate Secretary and Acting Principal Financial Officer, to serve as the Company’s Chief Financial Officer, effective June 1, 2024.”
CervoMed Inc. reported first quarter ended March 31, 2024 results: net income approximately $2.5 million.
“Net income was approximately $2.5 million for the three months ended March 31, 2024”
CervoMed Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.
“CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing financial results as of and for the quarter and full year ended December 31, 2023. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.”
CervoMed Inc. entered into Purchase Agreement with purchasers named therein valued at approximately $50 million (effective 2024-03-28).
“On March 28, 2024, CervoMed Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of an aggregate of 2,532,285 units”
CervoMed Inc. amended Amendment with The Joshua S. Boger 2021 Trust DTD 12/09/2021 (effective 2024-02-26).
“☐ 1 Item 1.01 Entry into a Material Definitive Agreement Amendment to Pre-Funded Warrant As previously disclosed, on August 16, 2023, CervoMed Inc.”
Joshua S. Boger was appointed as Chair of the Board at CervoMed Inc..
“On February 5, 2024, the Board of Directors (the “Board”) of CervoMed Inc. (the “Company”) appointed Joshua S. Boger, Ph.D., as a director of the Company and as Chair of the Board, effective February 7, 2024.”
CervoMed Inc. reported financial results for Third Quarter 2023.
“CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study Completed reverse merger; company now publicly traded on Nasdaq ( “ CRVO ” ) CervoMed has cash runway through the end of 2024, by which time the topline primary efficacy results from the Phase 2b RewinD-LB study are expected to be available BOSTON, MA – November 13, 2023 – CervoMed Inc. (NASDAQ: CRVO) , a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced financial results for the third quarter ended September 30, 2023, and provided recent business highlights.”
Robert J. Cobuzzi, Jr., Ph.D. was appointed as Director at CervoMed Inc..
“On November 7, 2023, the Board of Directors (the “Board”) of CervoMed Inc. (the “Company”) appointed Robert J. Cobuzzi, Jr., Ph.D., as a director of the Company, effective immediately.”
Jill Davidson departed as Director at CervoMed Inc..
“On October 25, 2023, Jill Davidson notified CervoMed Inc. (the “Company”) that she was resigning from the Board of Directors (the “Board”) of the Company, effective November 1, 2023.”
CervoMed Inc. shareholders approved To approve a postponement or adjournment of the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposals set forth above at the 2023-08-15 meeting.
“Proposal 3. To approve a postponement or adjournment of the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposals set forth above: 779,597 For 323,300 Against 8,892 Abstain 0 Broker Non-Votes”
CervoMed Inc. shareholders approved To approve an amendment to the certificate of incorporation, as amended, of Diffusion to effect a reverse stock split of Diffusion common stock at a ratio within the range between 1.5-for-1 to 8-for-1 at the 2023-08-15 meeting.
“Proposal 2. To approve an amendment to the certificate of incorporation, as amended, of Diffusion to effect a reverse stock split of Diffusion common stock at a ratio within the range between 1.5-for-1 to 8-for-1: 859,259 For 305,881 Against 7,059 Abstain 0 Broker Non-Votes”
CervoMed Inc. shareholders approved To approve the issuance of shares of Diffusion capital stock pursuant to the Merger, which will represent more than 20% of the shares of Diffusion common stock outstanding immediately prior to the Merger and result in a change of control of Diffusion, pursuant to Nasdaq Listing Rules 5635(a) and 563 at the 2023-08-15 meeting.
“Proposal 1. To approve the issuance of shares of Diffusion capital stock pursuant to the Merger, which will represent more than 20% of the shares of Diffusion common stock outstanding immediately prior to the Merger and result in a change of control of Diffusion, pursuant to Nasdaq Listing Rules 5635(a) and 5635(b): 521,953 For 203,636 Against 6,303 Abstain 440,307 Broker Non-Votes”
CervoMed Inc. underwent a change of control involving EIP Pharma, Inc. (closed 2023-08-16).
“Diffusion, Merger Sub and EIP consummated the transactions contemplated by the Merger Agreement.”
Frank Zavrl was appointed as Director at CervoMed Inc..
“Pursuant to the terms of the Merger Agreement, each of (i) John Alam, M.D., Sylvie Grégoire, PharmD., Jeff Poulton, Marwan Sabbagh, M.D., and Frank Zavrl were appointed to the board of directors of the Company as designees of EIP”
Marwan Sabbagh, M.D. was appointed as Director at CervoMed Inc..
“Pursuant to the terms of the Merger Agreement, each of (i) John Alam, M.D., Sylvie Grégoire, PharmD., Jeff Poulton, Marwan Sabbagh, M.D., and Frank Zavrl were appointed to the board of directors of the Company as designees of EIP”
Jeff Poulton was appointed as Director at CervoMed Inc..
“Pursuant to the terms of the Merger Agreement, each of (i) John Alam, M.D., Sylvie Grégoire, PharmD., Jeff Poulton, Marwan Sabbagh, M.D., and Frank Zavrl were appointed to the board of directors of the Company as designees of EIP”
Sylvie Grégoire, PharmD. was appointed as Chair of the Board of Directors at CervoMed Inc..
“Dr. Grégoire was appointed Chair of the Company’s board of directors.”
William Tanner, Ph.D. was appointed as Chief Financial Officer at CervoMed Inc..
“William Tanner, Ph.D has served as the Company’s Chief Financial Officer since August 2023.”
John Alam, M.D. was appointed as Chief Executive Officer at CervoMed Inc..
“John Alam, MD has served as the President and Chief Executive Officer of the Company since August 2023.”
William Elder changed role as General Counsel and Corporate Secretary at CervoMed Inc..
“William Elder will step down from his role as Principal Financial Officer and will remain employed by the Company as the General Counsel and Corporate Secretary of the Company.”
Robert J. Cobuzzi Jr., Ph.D. was appointed as Chief Operating Officer at CervoMed Inc..
“Robert J. Cobuzzi Jr., Ph.D., the Company’s Chief Executive Officer, resigned as the Company’s Chief Executive Officer and as a director of the Company, in each case, as of the Effective Time and was appointed as Chief Operating Officer.”
Diana Lanchoney, M.D. resigned as Director at CervoMed Inc..
“each of Alan Levin, Robert Adams, J.D., Mark T. Giles, J.D. and Diana Lanchoney, M.D. resigned from Diffusion’s board of directors”
Mark T. Giles, J.D. resigned as Director at CervoMed Inc..
“each of Alan Levin, Robert Adams, J.D., Mark T. Giles, J.D. and Diana Lanchoney, M.D. resigned from Diffusion’s board of directors”
Robert Adams, J.D. resigned as Director at CervoMed Inc..
“each of Alan Levin, Robert Adams, J.D., Mark T. Giles, J.D. and Diana Lanchoney, M.D. resigned from Diffusion’s board of directors”
Alan Levin resigned as Director at CervoMed Inc..
“each of Alan Levin, Robert Adams, J.D., Mark T. Giles, J.D. and Diana Lanchoney, M.D. resigned from Diffusion’s board of directors”
Jill Davidson was appointed as director at CervoMed Inc..
“Effective July 26, 2023, the Board of Directors (the “Board”) of Diffusion Pharmaceuticals Inc. (the “Company”) appointed Jill Davidson as a director of the Company.”
William Elder was appointed as principal financial officer at CervoMed Inc..
“On June 14, 2023, following the previously reported departure of the former Chief Financial Officer of Diffusion Pharmaceuticals Inc. (“Diffusion” or the “Company”), the Company’s board of directors appointed William Elder, Diffusion’s General Counsel and Corporate Secretary, as the Company’s principal financial officer.”
William K. Hornung departed as Chief Financial Officer at CervoMed Inc..
“Effective as of the close of business on May 15, 2023, Mr. William K. Hornung departed Diffusion Pharmaceuticals Inc.”
CervoMed Inc. entered into Agreement and Plan of Merger with Diffusion Pharmaceuticals Inc. valued at EIP Pharma, Inc. to be acquired by Diffusion Pharmaceuticals Inc.; former EIP stockholders to own ~7 (effective 2023-03-30).
“On March 30, 2023, Diffusion Pharmaceuticals Inc., a Delaware corporation (“ Diffusion ” or “ Parent ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), by and among Diffusion, EIP Pharma, Inc., a Delaware corporation (“ EIP ” or the “ Company ”), and Dawn Merger Sub Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Diffusion (“ Merger Sub ”), pursuant to which, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will be merged with and into EIP (the “ Merger ”) at the effective time of the Merger (the “ Effective Time ”), with EIP continuing after the Merger as the surviving corporation and a wholly-owned subsidiary of Diffusion.”
CervoMed Inc. announced a restructuring with charges of approximately $1.1 million affecting clinical operations function (six of the Company’s 13 current employees).
“Diffusion expects to record a one-time charge of approximately $1.1 million in the first quarter of 2023 in connection with the reduction in force, primarily related to one-time termination benefits to be paid in cash, which is expected to be completed in March 2023.”
Christopher D. Galloway departed as Chief Medical Officer at CervoMed Inc..
“As part of the reduction in force, the Company determined that Dr. Christopher D. Galloway, M.D., the Company’s Chief Medical Officer, will depart Diffusion effective March 1, 2023.”
CervoMed Inc. shareholders approved Advisory approval of named executive officer compensation at the 2022-12-30 meeting.
“The approval of Proposal No. 3 required the affirmative vote of a majority of the votes present and entitled to vote at the Annual Meeting and, accordingly, Proposal No. 3 received the requisite number of votes for approval at the Annual Meeting.”
CervoMed Inc. shareholders approved Ratify the selection of KPMG LLP as independent registered public accounting firm at the 2022-12-30 meeting.
“The approval of Proposal No. 2 required the affirmative vote of a majority of the votes present and entitled to vote at the Annual Meeting and, accordingly, Proposal No. 2 received the requisite number of votes for approval at the Annual Meeting.”
CervoMed Inc. shareholders approved Election of six directors at the 2022-12-30 meeting.
“The election of each nominee pursuant to Proposal No. 1 required the affirmative vote of a plurality of the votes present and entitled to vote at the Annual Meeting and, accordingly, each nominee received the requisite number of votes for election at the Annual Meeting.”
CervoMed Inc. entered into Agreement with LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates (effective 2022-12-15).
“On December 15, 2022, Diffusion Pharmaceuticals Inc. (the “ Company ”) entered into a binding settlement agreement (the “ Agreement ”) with LifeSci Special Opportunities Master Fund Ltd. and certain of its affiliates (collectively, “ LifeSci Special Opportunities ”)”
CervoMed Inc. reported financial results for the three-month period ended September 30, 2022.
“On November 14, 2022, Diffusion Pharmaceuticals Inc. (the “Company”) issued a press release announcing financial results for the three-month period ended September 30, 2022 and a business update.”
Eric Francois resigned as director at CervoMed Inc..
“On November 13, 2022, Eric Francois resigned from the board of directors (the “Board”) of Diffusion Pharmaceuticals Inc. (the “Company”) and all committees and subcommittees thereof, effective as of December 16, 2022.”
Raven Jaeger was appointed as Chief Regulatory Officer at CervoMed Inc..
“As previously disclosed, on May 18, 2022, Raven Jaeger, M.S., was appointed as the Chief Regulatory Officer of Diffusion Pharmaceuticals Inc.”
Raven Jaeger was appointed as Chief Regulatory Officer at CervoMed Inc..
“On May 18, 2022, Raven Jaeger, M.S., was appointed as the Chief Regulatory Officer of Diffusion Pharmaceuticals Inc.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.